Delivery Order SPE2DB22D3016-SPE2DB25FAQT4

Award Date 3/10/25
Potential Completion Date 3/31/25
Potential Value $31K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of CABOMETYX 40 MG TABLET 30S. The $61,386.20 firm fixed-price delivery order contract has an ultimate completion date of March 27, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $15,346.55, is for the supply of CABOMETYX 40 MG TABLET 30S, a pharmaceutical product. The award has an ultimate completion date of March 27, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award, with the ID SPE2DB20D3101|SPE2DB24FRKZ9, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,867.18 firm fixed-price delivery order is for the provision of CABOMETYX 40 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of June 13, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC)...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $30,693.10 firm fixed-price delivery order is for the supply of CABOMETYX 40 MG TABLET 30S, a pharmaceutical product, with a period of performance through March 11, 2025. This award is part of AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $28,777.92 fixed-price delivery order is for CABOMETYX 60 MG TABLET 30S, a specialty medication, with a period of performance through December 23, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as a primary...
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of one of the largest pharmaceutical distributors in the world, is for the delivery of CABOMETYX 20 MG TABLET 30S to the Defense Logistics Agency (DLA). The $14,035.64 firm fixed-price delivery order has an ultimate completion date of August 1, 2024. The contract is not set-aside and is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, identified as SPE2DX15D1022|SPE2DX25FVCRL, is a Delivery Order with a Firm Fixed Price type and a ceiling value of $15,301.05. The contract is for the delivery of CABOMETYX 60 MG TABLET 30S, a pharmaceutical product, with a performance period through March 18, 2025....
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The $15,346.55 contract is for the supply of CABOMETYX 40 MG TABLET 30S, a specialty medication. The contract has an ultimate completion date of March 25, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $15,301.05 firm fixed-price delivery order is for the supply of CABOMETYX 60 MG TABLET 30S, a medication used in the treatment of certain types of cancer. The contract has an ultimate completion date of March 25, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award, valued at $56,142.56, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the delivery of CABOMETYX 20 MG TABLET 30S, a pharmaceutical product. The contract has a performance period through July 30, 2024 and is a firm-fixed price delivery order. This contract is not associated with any set-aside designation. Amerisourcebergen is a major supplier of pharmaceutical products and medical...
  • SPE2DB22D3016
    Indefinite Delivery Contract
  • SPE2DB22D3016-SPE2DB25FAQT4
    Delivery Order

This federal contract award, identified as SPE2DB22D3016|SPE2DB25FAQT4, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp. The $30,693.10 firm-fixed-price delivery order is for the supply of CABOMETYX 40 MG TABLET 30S, a prescription medication. The contract has an ultimate completion date of March 31, 2025.

AmerisourceBergen Drug Corp, a for-profit pharmaceutical distribution company, holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999 through November 2026. This IDC serves as the primary vehicle for providing a wide range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, covering similar medical products and prescription drugs.

The contract award reviewed does not have a set-aside designation, indicating open competition.

Generated 6/9/25, 9:54 AM